Market Place
Sourcing Support
FDA Issues Form 483 to Aarti Drugs Limited
01 Nov 2024 //
FDA
Aarti Drugs posts Q2 FY25 consolidated profit at Rs. 35.01 Cr
26 Oct 2024 //
INDPHARMAPOST
Aarti Drugs Gets Form 483 With 7 USFDA Observations At API Facility
20 Sep 2024 //
EQUITYBULL
Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr
30 Jul 2024 //
INDIANPHARMAPOST
Aarti Drugs posts Q4 FY24 consolidated PAT at Rs. 47.37 Cr
09 May 2024 //
INDINPHARMAPOST
Aarti Drugs posts Q3 FY24 consolidated PAT at Rs. 36.71 Cr
25 Jan 2024 //
INDIAN PHARMA POST
Aarti Drugs bags Pharmexcil Outstanding Exports Awards 2021-22
07 Jul 2023 //
INDIAN PHARMA POST
Aarti Drugs Q2 FY23 revenue up 19%; Profit down 5.6%
24 Oct 2022 //
INDIANPHARMAPOST
Aarti Drugs slips for second day
15 Dec 2021 //
BUSINESS-STANDARD
Aarti Drugs slumps 5% as Centre levies anti-dumping duty on Ciprofloxacin HCl
04 Sep 2020 //
IIFL
Aarti Drugs shares surge 13% on bonus issue plan announcement
17 Aug 2020 //
BUSINESS-STANDARD
Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing
29 Jul 2020 //
MONEYCONTROL
US FDA actions, DPCO hit sales & profits of top 30 cos in first half of 2016-17
21 Nov 2016 //
PHARMABIZ
Facilities of Aarti Drugs on USFDA Import Alert List
25 Mar 2015 //
FIERCE PHARMA MANUFACTURING
Aarti Drugs Tanks 17% On Import Alert For Maharashtra Unit
23 Mar 2015 //
MONEYCONTROL
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.